This post is from a suggested group
Obesity Treatment
Are GLP-1 drugs the end of bariatric surgery and lifestyle interventions?
A (Bariatric Surgeon): No. Surgery still achieves greater and more durable weight loss. Roux-en-Y gastric bypass (RYGB) achieves 30-35% total weight loss at 5 years, compared to 15-20% for GLP-1s. For patients with BMI > 40 or with severe comorbidities, surgery is superior. Also, surgery is one-time cost (~$25,000) vs. lifetime drug cost (~$12,000/year).
B (Endocrinologist - Obesity Medicine): But patients don't want scalpels. Oral formulations of GLP-1s (semaglutide pill, danuglipron) are coming. Adherence will be higher than injections. Also, combination therapy—low-dose GLP-1 plus lifestyle—may be the optimal approach for many, avoiding both surgery and high-dose drug side effects.
C (Health Ethicist): We are medicalizing a societal problem. These drugs treat the symptom (excess weight) but not the cause (food environment, food deserts, ultra-processed foods, stress, sleep deprivation). Who pays for a lifetime of $1,200/month injections for 40% of…